All News

29 July 2009

European commission approves broader label for Avastin allowing combination with docetaxel for the first-line treatment of advanced (metastatic) breast cancerAntibodies

29 July 2009

BTG plc: AstraZeneca to progress CytoFab™ into Phase IIb studyAntibodies

28 July 2009

Active Biotech’s Cancer Project ANYARA Featured in Journal of Clinical OncologyAntibodies

27 July 2009

Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)Antibodies

24 July 2009

Merck KGaA Considers Appealing CHMP Opinion on Erbitux ATreatment for Non-Small Cell Lung CancerAntibodies

24 July 2009

Ilaris® recommended for European approval as new biologic drug to treat a rare but serious group of auto-inflammatory diseasesAntibodies

24 July 2009

Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical TrialAntibodies

24 July 2009

Regeneron Receives European Medicines Agency Positive Opinion for Marketing Authorization of Rilonacept for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)Antibodies

24 July 2009

MabThera receives positive opinion in Europe for treating patients whose chronic lymphocytic leukaemia returnsAntibodies

24 July 2009

OMT Announces a Breakthrough in the Development of a Novel Human Antibody PlatformAntibodies

24 July 2009

RECRUITMENT COMPLETED IN ARZERRA™ (OFATUMUMAB) PHASE II STUDY IN RELAPSED DLBCLAntibodies

23 July 2009

First Patient Enrolled in Regeneron and Bayer HealthCare VEGF Trap-Eye Phase 3 Program in Central Retinal Vein OcclusionAntibodies

22 July 2009

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to AffitechAntibodies

20 July 2009

Human Genome Sciences and GlaxoSmithKline announce positive Phase 3 study results for Benlysta™ in systemic lupus erythematosusAntibodies

20 July 2009

ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX® (cetuximab) U.S. Product Labeling for Metastatic Colorectal CancerAntibodies

20 July 2009

Nycomed announces FDA filing for Daxas® in COPDAntibodies

16 July 2009

GENMAB ANNOUNCES LIFT OF ZALUTUMUMAB PARTIAL CLINICAL HOLDAntibodies

16 July 2009

Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer’s Disease At ICAD Annual MeetingAntibodies

15 July 2009

XOMA Announces Positive Results From U.S. Phase 1 Trial of XOMA 052 in Type 2 DiabetesAntibodies

15 July 2009

Baxter and Halozyme Announce Completion of Patient Enrollment in Phase III Pivotal Trial of GAMMAGARD LIQUID(TM) with rHuPH20 EnzymeAntibodies

15 July 2009

Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal AntibodiesAntibodies

15 July 2009

BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaAAntibodies

13 July 2009

MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile VirusAntibodies

13 July 2009

NovImmune successfully completes NI-0801 Phase I clinical studyAntibodies

10 July 2009

InNexus and Genhelix to Combine Antibody Development and Manufacturing ResourcesAntibodies

9 July 2009

Medarex and Lonza Sign Collaboration Agreement for the Supply of Antibody-Based ProductsAntibodies

9 July 2009

DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE SUPPORT USE OF RAXIBACUMAB (ABTHRAX™) FOR THE TREATMENT OF INHALATION ANTHRAXAntibodies

9 July 2009

RECRUITMENT COMPLETED IN ARZERRA™ (OFATUMUMAB) PIVOTAL CLL STUDYAntibodies

8 July 2009

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone MetastasesAntibodies

8 July 2009

ENBREL to Add Indication of Juvenile Idiopathic Arthritis (JIA)Antibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

TL1A Inhibitor Pipeline Review

Report Package: “Drug the Undruggable” Technologies

B7-H4 Targeted Antibody Therapy Pipeline Review

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

DLL3-Targeted Immunotherapy Candidates Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective